No Data
No Data
Morgan Stanley Maintains Johnson & Johnson(JNJ.US) With Hold Rating, Maintains Target Price $167
Morgan Stanley analyst Terence Flynn maintains $Johnson & Johnson(JNJ.US)$ with a hold rating, and maintains the target price at $167.According to TipRanks data, the analyst has a success rate of 64.8
Johnson & Johnson (JNJ.US) announced the acquisition of Yellow Jersey will bring a cost impact of 1.25 billion US dollars, it is expected to dilute this year's adjusted EPS by 0.56 US dollars.
Johnson & Johnson announced on Thursday that the acquisition of Yellow Jersey Therapeutics will result in an expense impact of approximately $1.25 billion.
J&J to Recognize $1.25B Impact From Yellow Jersey Acquisition
Express News | Johnson & Johnson Completes The Acquisition Of Yellow Jersey, A Demerged Subsidiary Of Numab Therapeutics To Secure The Global Rights To Nm26, In An All-cash Transaction Of Approximately $1.25 Billion, As Announced On May 28, 2024
Express News | Johnson & Johnson Strengthens Pipeline to Lead in Atopic Dermatitis With the Completion of the Acquisition of Yellow Jersey Therapeutics, Gaining Ownership of Nm26
Wells Fargo Maintains Johnson & Johnson(JNJ.US) With Hold Rating, Maintains Target Price $163
Wells Fargo analyst Larry Biegelsen maintains $Johnson & Johnson(JNJ.US)$ with a hold rating, and maintains the target price at $163.According to TipRanks data, the analyst has a success rate of 58.1%
loading...
No Data